全文获取类型
收费全文 | 1652578篇 |
免费 | 111979篇 |
国内免费 | 2583篇 |
专业分类
耳鼻咽喉 | 22934篇 |
儿科学 | 53614篇 |
妇产科学 | 43387篇 |
基础医学 | 244098篇 |
口腔科学 | 46392篇 |
临床医学 | 149157篇 |
内科学 | 311039篇 |
皮肤病学 | 37590篇 |
神经病学 | 122416篇 |
特种医学 | 63553篇 |
外国民族医学 | 276篇 |
外科学 | 247823篇 |
综合类 | 34149篇 |
现状与发展 | 3篇 |
一般理论 | 411篇 |
预防医学 | 119044篇 |
眼科学 | 38516篇 |
药学 | 129964篇 |
10篇 | |
中国医学 | 4711篇 |
肿瘤学 | 98053篇 |
出版年
2019年 | 12375篇 |
2018年 | 17764篇 |
2017年 | 13920篇 |
2016年 | 15606篇 |
2015年 | 17442篇 |
2014年 | 23797篇 |
2013年 | 35240篇 |
2012年 | 47705篇 |
2011年 | 50361篇 |
2010年 | 29577篇 |
2009年 | 27841篇 |
2008年 | 46598篇 |
2007年 | 50015篇 |
2006年 | 50876篇 |
2005年 | 48036篇 |
2004年 | 46378篇 |
2003年 | 44471篇 |
2002年 | 42997篇 |
2001年 | 86680篇 |
2000年 | 88633篇 |
1999年 | 73665篇 |
1998年 | 18883篇 |
1997年 | 16417篇 |
1996年 | 16609篇 |
1995年 | 15719篇 |
1994年 | 14267篇 |
1993年 | 13431篇 |
1992年 | 55533篇 |
1991年 | 54267篇 |
1990年 | 53168篇 |
1989年 | 51596篇 |
1988年 | 46674篇 |
1987年 | 45433篇 |
1986年 | 43054篇 |
1985年 | 40382篇 |
1984年 | 29512篇 |
1983年 | 24961篇 |
1982年 | 13860篇 |
1979年 | 26702篇 |
1978年 | 18341篇 |
1977年 | 16040篇 |
1976年 | 14476篇 |
1975年 | 16380篇 |
1974年 | 19088篇 |
1973年 | 18396篇 |
1972年 | 17499篇 |
1971年 | 16377篇 |
1970年 | 15331篇 |
1969年 | 14524篇 |
1968年 | 13050篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
82.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
83.
C. M. de Bont N. Eerden W. C. Boelens G. J. M. Pruijn 《Clinical and experimental immunology》2020,199(1):1-8
Neutrophils can form neutrophil extracellular traps (NETs) to capture microbes and facilitate their clearance. NETs consist of decondensed chromatin decorated with anti-microbial proteins. Here, we describe the effect of neutrophil proteases on the protein content of NETs. We show that the neutrophil serine proteases degrade several neutrophil proteins associated with NETs. Interestingly, the anti-bacterial proteins associated with NETs, such as myeloperoxidase, calgranulin B and neutrophil elastase (NE), seem to be less susceptible to proteolytic degradation than other NET proteins, such as actin and MNDA. NETs have been proposed to play a role in autoimmune reactions. Our data demonstrate that a large number of the autoepitopes of NET proteins that are recognized by autoantibodies produced by systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients are also removed by the proteases. In conclusion, neutrophil serine proteases have a major impact on the NET proteome and the proteolytic changes of NET-associated proteins may counteract autoimmune reactions to NET components. 相似文献
84.
Walid K. Abu Saleh Phillip Mason Odeaa Al Jabbari Hany Samir Brian A. Bruckner 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(6):569-571
The Impella 5.0, a percutaneously inserted left ventricular assist device, has been used to support patients who have severe heart failure or who are undergoing high-risk percutaneous coronary intervention. We report our surgical placement of the Impella 5.0, through a graft sewn to the aorta, to unload the left ventricle of a 59-year-old man who was undergoing venoarterial extracorporeal membrane oxygenation for postcardiotomy shock. The patient underwent successful placement of a long-term left ventricular assist device before his discharge from the hospital. The versatility of the Impella 5.0 is exemplified in this patient who was successfully bridged to long-term support. 相似文献
85.
More than just crushing: a prospective pre‐post intervention study to reduce drug preparation errors in patients with feeding tubes
下载免费PDF全文
![点击此处可从《Journal of clinical pharmacy and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
86.
87.
88.
89.
90.